{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093314","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.535965+00:00","generated_at":"2026-05-31T11:07:47.876221+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cullinan Q2 net loss $42M; cash $664.9M; advancing CLN-978 IND in SLE for Q3 2024","bullets":["Net loss $42.0M vs $32.2M Q2 2023; R&D $36.3M, G&A $13.8M; cash runway into 2028.","CLN-978 (CD19xCD3 T cell engager) IND for SLE on track for Q3 2024; pursuing RA with FAU Erlangen & Università Cattolica.","CLN-619 combo data at ASCO showed objective responses in oncogenic mutation NSCLC; expansion cohorts added.","Positive initial zipalertinib data from REZILIENT1 study; ESMO presentation planned.","Discontinued CLN-418; returned rights to Harbour BioMed. Oversubscribed PIPE raised $280M in April."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093314","json":"https://secwatch.observer/filing/0000950170-24-093314.json","markdown":"https://secwatch.observer/filing/0000950170-24-093314.md","text":"https://secwatch.observer/filing/0000950170-24-093314.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024093314/0000950170-24-093314-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024093314/cgem-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:07:47.876221+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}